Clinical and prognostic analyses of 110 patients with N3 nasopharyngeal carcinoma

Jing Chen, MD, Tongxin Liu, MD, Quanquan Sun, MD, Fujun Hu, MD*

Abstract

Objective: To analyze the clinical outcome and prognostic factors of N3 nasopharyngeal carcinomas (NPCs), provide a basis for rational treatment and improve the cure rate.

Methods: A total of 110 patients with a pathologically confirmed diagnosis of N3 (NPC 2008 stage in China) NPC from our hospital were retrospectively included in the study conducted from April 2007 to July 2011. All patients received intensity-modulated radiation therapy. Some of these patients received various chemotherapies. The doses of the planning gross primary tumor and retropharyngeal lymph node volume, high-risk planning tumor volume, low-risk planning tumor volume, and gross tumor volume of neck lymph nodes were 6000 to 7600, 5400 to 6600, 5000 to 6000, and 6000 to 6996 cGy, respectively. The Kaplan–Meier analysis and logrank test were carried out to calculate and compare the survival rates of the patients, and the Statistical Package for the Social Sciences software version 17.0 was used for all analyses. Meanwhile, the Cox model was used to analyze the prognostic factors.

Results: In this study, the 1-, 3-, and 5-year overall survival rates of the patients were 92.63%, 83.16%, and 70.53%, respectively. Based on the univariate analysis, T stage (P = .043) and chemotherapy (P = .003) were significant factors for survival. In the multivariate analysis, only chemotherapy influenced survival (Table 1). Recent toxicity included radioactive oral mucosa inflammation and skin injury, and difficulty opening the mouth and hearing loss were considered late adverse reactions. None of the patients died during treatment.

Conclusions: Patients with N3 NPC are at high risk of distant metastasis, and their 5-year survival rate is poor. The more important prognostic factors were T stage and chemotherapy. Patients with N3 NPC should be treated with combined chemotherapy and radiotherapy.

Abbreviations: AdjCT = adjuvant chemotherapy, CCRT = concurrent chemotherapy, CR = complete remission, IMRT = intensity-modulated radiation therapy, IndCT = induced chemotherapy, MRI = magnetic resonance imaging, NPC = nasopharyngeal carcinoma, PD = progressive disease, PR = partial remission, RT = radiation therapy, SD = stable disease.

Keywords: chemotherapy, N3, nasopharyngeal carcinoma, radiotherapy

1. Introduction

Nasopharyngeal carcinoma (NPC) is a malignant tumor of the epithelial tissue, and the incidence of NPC differs in terms of age, race, and geography. The incidence rate of NPC is approximately 14.6/100,000 populations.[1] The intergroup 0099 randomized trial has proven that concurrent chemoradiotherapy (CRT) followed by adjuvant chemotherapy (AdjCT) is superior to radiotherapy alone in the treatment of advanced-stage NPC.[2] However, 3 earlier randomized trials have shown that adding AdjCT to radiotherapy did not improve survival.[3–5]

Individuals with N3 NPC are at high risk for distant metastasis. Local recurrence and distant metastasis are important factors that influence the survival and prognosis of patients with such condition. Radiation therapy (RT) is the primary treatment for NPC because of its inherent anatomic constraints and a high degree of radiosensitivity. However, NPC is also a chemosensitive tumor. Thus, a great deal of focus has been placed on combined RT and chemotherapy in the treatment of locoregionally advanced NPC. Thus, a retrospective analysis of 110 patients with N3 NPC has been conducted. Moreover, this study aimed to analyze the curative effect of the treatments and to identify the clinical features of NPC to further develop the clinical basis for the stratification of chemotherapies for locally advanced NPC.

2. Materials and methods

2.1. Clinical data

The study was approved by the ethics committee of Zhejiang Cancer Hospital. Informed consent forms were obtained from the patients. In total, 110 patients with N3 NPC were treated in Zhejiang Cancer Hospital from April 2007 to July 2011. Of these patients, 84 were men and 26 were women. The male-to-female ratio is 3.23:1. The age of the participants ranged from 26 to 81 years, with an average of 49.16 ± 10.61 years. The first symptoms were as follows: neck masses in 75 (68.18%) patients, nasal congestion in 12 (10.91%) patients, headache in 7 (6.36%)
2.2. Treatment method

2.2.1. Radiotherapy. All patients received intensity-modulated RT, and the doses for planning gross primary tumor and retropharyngeal lymph node volume (PTVnx+rn), high-risk planning tumor volume (PTV1), low-risk planning tumor volume (PTV2), and gross tumor volume of neck lymph nodes (GTVnd) were 6000 to 7600 Gy, 5400 to 6600 Gy, 5000 to 6000 Gy, and 6000 to 6996 Gy, respectively. The dose for important functional organs and endangered organs was limited. The maximum doses (Dmax) for the brain stem, spinal cord, optic nerve, and chiasm, temporomandibular joint, temporal lobe, crystal, mandible, and 50% volume parotid were ≤54 Gy, ≤40 Gy, ≤54, ≤50, ≤54 to 60, ≤8, ≤60, and ≤30 Gy, respectively. The Pinnacle 7.6 planning system was used to design the plans through synchronous integrated technology (SMART boost), and the physician outlined the target areas and normal tissues and set the prescription dose and endanger organ dose. The physical therapist established and optimized the intensity-modulated RT (IMRT) plan. The evaluation of treatment plan included the target region, endanger organ dose volume histogram, and layer evaluation of each equal section. The doctors first confirmed the treatment plan, and then, dosimetric verification was performed. Finally, RT was carried out.

2.2.2. Chemotherapy. All patients received IMRT and various chemotherapy. Meanwhile, 95 patients received induced chemotherapy (IndCT), of whom, 39 and 56 received PF and TP, respectively. PF comprised nedaplatin (NDP) 75 mg/m² on days 1 to 3, tegafur 1 g on days 1 to 3, or 5-Fu 300 to 500 mg/m² via continuous intravenous injection (CIV) 72 to 120 hours for 21 days/cycle. Meanwhile, TP comprised docetaxel 75 mg/m² on day 1, DDP 75 mg/m² on days 1 to 3 for 21 days/cycle. Radiotherapy or concurrent chemotherapy (CCRT) was carried out after 2 to 4 cycles of IndCT. CCRT was based on NDP or DPP 80 mg/m² on days 1 to 3 every 21 days. In total, 103 patients received 1 to 2 cycles of CCRT. AdjCT was performed around 1 month after radiotherapy, and a total of 53 patients received FP comprising NDP 75 mg/m² on days 1 to 3, tegafur 1 g on days 1 to 3, or 5-Fu 300 to 500 mg/m² via CIV 72 to 120 hours for 21 days/cycle. Seven patients received platinum-based regimen. In total, all chemotherapy regimens consisted of 2 to 3 cycles.

2.3. Observation and follow-up during treatment

Biochemical and routine blood tests were carried out every week during treatment. The acute responses of patients to radiotherapy and chemotherapy were recorded. Tumor regression was assessed using the nasopharyngoscopy scope or via indirect nasopharyngoscopy every 7 to 10 days. Acute toxicity and late adverse reaction evaluation criteria referred to LENT SOMA and Common Terminology Criteria for Adverse Events version 3.0 (CTCAE3.0) grade evaluation criteria. Nasopharyngoscopy scope was used and magnetic resonance imaging (MRI), chest radiography, blood test, and B-ultrasonography were conducted to assess the local control rate. Moreover, the side effects of radiotherapy were recorded. We can evaluate the control rate and identify the side effects of radiotherapy by reexamining the MRI, rhinitis fibrosis, chest radiography, B-ultrasonography, and electroconvulsive therapy before treatment. Disease stage was N2M0 (2008 UICC).

### Table 1

| Factors | 5-year survival% | P (univariate) | P (multivariate) |
|---------|-----------------|---------------|-----------------|
| Sex     |                 |               |                 |
| Male    | 68.65           | .776          | .375            |
| Female  | 73.22           |               |                 |
| Age     |                 |               |                 |
| <60     | 65.84           | .069          | .374            |
| >60     | 77.13           |               |                 |
| T stage |                 |               |                 |
| T1      | 85.23           | .025          | .553            |
| T2      | 82.75           |               |                 |
| T3      | 72.33           |               |                 |
| T4      | 64.96           |               |                 |
| Chemotherapy |        |               |                 |
| No AdjCT | 67.74         | .214          | .378            |
| AdjCT   | 72.68           |               |                 |
| No IndCT | 60.97         | x² = 6.207    |                 |
| IndCT   | 81.51           | .003          | .014            |

AdjCT = adjuvant chemotherapy, CCRT = concurrent chemotherapy, DFS = disease-free survival, DMFS = distant metastasis-free survival, IndCT = induced chemotherapy, OS = overall survival.

### 3. Results

3.1. Treatment outcome

In this study, the median survival time of the patients was 44.5 months. The 1-, 3-, and 5-year overall survival (OS) rates were 92.63%, 83.16%, and 70.53%, respectively. The univariate analysis showed that T stage (P=.043) and chemotherapy
were significant factors of survival. Based on the multivariate analysis, only chemotherapy influenced survival rate. The median follow-up time was 70.5 months. During the follow-up, relapse was observed in 27 (24.5%) patients. Moreover, there were 8 (7.3%), 12 (10.9%), and 7 (6.4%) cases of nasopharyngeal, cervical lymph node, and nasopharyngeal and cervical lymph node recurrence, respectively. Distant metastasis occurred in 72 (65.45%) patients. Bone, lung, and liver metastases were observed in 47 (42.73%), 13 (11.82%), and 8 (7.27%) patients, respectively, and another 4 patients presented with multiple metastasis, which accounts for 3.64% of all metastatic cases. Distant metastasis was mainly observed in the first and second years after treatment. In this study, induction chemotherapy+concurrent chemoradiotherapy were compared with concurrent chemoradiotherapy alone. A significant difference was observed in terms of the 5-year OS (76.5% vs 70.3%; P = .012), DFS (71.2% vs 67.8%; P = .036), and DMFS (69.4% vs 64.9%; P = .025). Patients with N3 NPC should be treated with combined chemotherapy and radiotherapy.

3.2. Adverse reaction and evaluation

In induction chemotherapy, 3 levels of adverse reactions were observed, which were mainly leukopenia, thrombocytopenia, and cardiac insufficiency (Table 2). The adverse reactions were relieved after treatment. Two patients with grade 4 granulocytopenia and 1 patient with heart failure were delayed for chemotherapy for more than 1 week. The drug dose was decreased by 10% in the next cycle of chemotherapy if the adverse reactions occurred in 25 (22.73%) patients, and 32 (29.09%) patients presented with first-degree radioactive damage. These patients recovered after treatment with recombinant human epidermal growth factor gel. Late adverse reactions included difficulty in opening the mouth and hearing loss. In total, 10 (9.09%) patients presented with limited jaw movements. Auditory nerve injury was observed in 16 (14.35%) patients. Meanwhile, neck fibrosis occurred in 6 (5.45%) patients. A comprehensive review was conducted to evaluate the effect after treatments. In total, 46, 56, 9, and 4 patients presented with CR, PR, SD, and PD, respectively. The clinical beneficial rate was 96.36%. Meanwhile, the objective response rate was 88.18%.

### Table 2

| Adverse reactions                  | CTCAE number (%) |
|-----------------------------------|------------------|
|                                   | 1 level | 2 level | 3 level | 4 level |
| Neutropenia                       | 21 (9.1) | 10 (0.9) | 5 (4.5) | 1 (0.9) |
| Hemoglobin decrease               | 18 (6.4) | 3 (2.7)  |        |        |
| Thrombocytopenia                  | 17 (5.5) | 12 (10.9)|        |        |
| Serum albumin decreased           | 9 (6.2)  | 4 (3.6)  |        |        |
| ALT increased                     | 12 (10.9)| 4 (3.6)  |        |        |
| AST increased                     | 9 (6.2)  |        |        |        |
| Total bilirubin                   | 7 (6.4)  |        |        |        |
| Urea nitrogen increased           | 3 (2.7)  |        |        |        |
| Elevated serum creatinine         | 2 (1.8)  |        |        |        |
| Cardiovascular system abnormalities| 10 (0.9)| 1 (0.9)  |        |        |

ALT = alanine transaminase, AST = aspartate transaminase, CTCAE = Common Terminology Criteria for Adverse Events.

**4. Discussion and conclusion**

Individuals with N3 NPC are at high risk of distant metastasis. Local recurrence and distant metastasis are important factors that influence the survival and prognosis of patients with NPC. In our study, 8 (7.3%), 12 (10.9%), and 7 (6.4%) patients presented with nasopharyngeal, cervical lymph node, and nasopharyngeal and cervical lymph node recurrence, respectively. Distant metastasis occurred in 72 (65.45%) patients. Concurrent CRT plus AdjCT has been the standard therapy for these patients for more than a decade. Moreover, the latest guidelines still include concurrent CRT plus AdjCT as an option for these patients.

Significant toxicity has been observed in patients who receive AdjCT after concurrent CRT. Several multicenter trials have reported that only around 60% to 70% of patients could tolerate the entire AdjCT regimen. Therefore, many have questioned the contribution of AdjCT and advocated concurrent CRT alone.

Treatment failure of N3 NPC was attributed to a high rate of local recurrence and/or distant metastasis. However, advances in radiation oncology have significantly improved locoregional control, and treatment failure is now mainly due to distant metastasis. Although salvage systemic chemotherapy is usually recommended for patients with overt distant metastasis, the cure rate for metastatic NPC is extremely low.

Some retrospective studies have shown a 5-year survival rate of CRCRT alone. Distant metastasis is the most important determinant of the survival rates of patients. The effect of chemotherapy is proportional to the burden of the tumor. Timely selection of N3 patients who need more aggressive treatment may improve the treatment outcome. RT is the primary treatment for NPC because of its inherent anatomic constraints and a high degree of radiosensitivity. However, NPC is also a chemosensitive tumor. Thus, a great deal of focus has been placed on combined RT and chemotherapy in the treatment of locoregionally advanced NPC. In patients with such condition, concurrent chemoradiotherapy was used to improve the local control rate and decrease the incidence of nasopharyngeal recurrence.

In this study, induction chemotherapy+concurrent chemoradiotherapy were compared with concurrent chemoradiotherapy. A significant difference was observed in terms of the 3-year OS (76.5% vs 70.3%; P = .012), DFS (71.2% vs 67.8%; P = .036), and DMFS (69.4% vs 64.9%; P = .025) (Figs. 1–3). TAN compared the patients with locally advanced NPC treated with induction chemotherapy and concurrent chemo-radiotherapy from those receiving CCRT alone. Patients were stratified by N stage and randomized to induction GCP (3 cycles of gemcitabine + carboplatin + paclitaxel) followed by CCRT or CCRT alone. No significant difference was observed in terms of the 3-year OS 94 (3% vs 92.1%); P = .494, DFS (74.9% vs 67.4%); P = .562), and DMFS (83.8% vs 79.9%); P = .547). The value of induction chemotherapy in clinical settings can be influenced by the short
follow-up time and non-high proportion of N\textsubscript{3} patients. In the ZHANG study,\textsuperscript{[12]} the 4-year OS, FFS, LRFS, and DMFS of the NCT and CRT groups were 87.5\% vs. 87.3\% (\(P = .595\)), 78.0\% vs 74.1\% (\(P = .304\)), 91.2\% vs 90.1\% (\(P = .96\)), and 88.2\% vs 84.4\% (\(P = .154\)), respectively, and no statistically significant difference was observed between the 2 groups. However, a subgroup analysis has found that paclitaxel-IndCT can significantly improve the IV b (T\textsubscript{3}N\textsubscript{3}M\textsubscript{0}) of NPC in terms of 4-year DMFS, DFS, and OS. Some scholars believe that the screening of high-risk patients, chemotherapeutic drug selection, and dosage

Figure 1. 5-year OS between patients who received IndCT plus CCRT and CCRT alone. CCRT = concurrent chemotherapy, IndCT = induced chemotherapy, OS = overall survival.

Figure 2. DFS between patients who received IndCT plus CCRT and CCRT alone. CCRT = concurrent chemotherapy, DMFS = distant metastasis-free survival, IndCT = induced chemotherapy.
and follow-up time can affect the evaluation of the value of chemotherapeutic treatment. The cumulative dose of chemotherapy drugs and chemotherapy treatment were positively correlated with long-term effect.\textsuperscript{[13]} Multiple meta-analyses have consistently shown that combination chemotherapy reduced local recurrence risk by 27\%–53\%.\textsuperscript{[14–16]} CCRT without AdjCT has also been accepted as another general treatment option with the support of phase 3 randomized trials.\textsuperscript{[17]} Recently, a trend toward increasing the use of IndCT has been observed, and several large phase 3 randomized trials have been conducted to compare the effect of IndCT plus CCRT versus CCRT alone.\textsuperscript{[18]} Despite these aggressive treatment strategies (CCRT plus AdjCT, IndCT plus CCRT, or CCRT alone), distant failure is still the most frequently reported mode of relapse.\textsuperscript{[17,19–26]} Because treatment only fails in some patients after initial definitive RT plus IndCT/ConCT, they believe that AdjCT is reasonable in consolidating treatment outcome for selected patients. Factors in the recurrence pattern of patients are gender, age, KPS score, and anemia.\textsuperscript{[27]} Whether patients with recurrence time of 1 to 2 years have unreasonable or more suggestive plans for the treatment remains to be elucidated. The recurrence of NPC after years may reflect the balance and imbalance between immune surveillance and the tumor. The recurrence in the nasopharynx can occur, and the survival rate of early local recurrence is higher than that of middle and late stage recurrence. Therefore, nasopharyngeal recurrence must be detected early. Moreover, 5 years of survival or 5 years of non-recurring survival is an artificial marker, and 5 years of survival is not a safe target for NPC. Moreover, a risk of recurrence after 5 or 10 years was observed. Therefore, follow-up time should be increased, and more active treatment for high-risk patients should be performed. In our study, 95 patients have received induction chemotherapy. In these cases, CCRT plus AdjCT was compared with CCRT, and no significant difference was observed in terms of 5-year OS (71.1\% vs 70.0\%; \textit{P} =.24), DFS (69.9\% vs 68.7\%; \textit{P} =.36), DMFS (67.6\% vs 68.1\%; \textit{P} =.055) (Figs. 4–6). Some scholars believe that distant failure is still the most frequently reported mode of relapse despite the availability of aggressive treatment strategies (CCRT plus AdjCT, IndCT plus CCRT, or CCRT alone).\textsuperscript{[26]} In a study conducted in Italy, no differences were observed in terms of survival between the patients who received RT alone and those who received RT plus 6 monthly cycles of AdjCT, and this trial has included more patients with low-risk for distant failure and used a less active drug combination.\textsuperscript{[5]} Similarly, a study in Taiwan has shown the efficacy of 9 weekly cycles of adjuvant PFL (cisplatin, 5-FU, and leucovorin) and reported that the treatment was not beneficial for overall or relapse-free survivals.\textsuperscript{[3]} A multicenter trial in China that enrolled 508 patients did not report any significant difference in survival benefits between patients treated with CCRT and those who received CCRT plus 3 monthly cycles of adjuvant PF chemotherapy for stage III and IVB diseases.\textsuperscript{[28]} Adjuvant PF chemotherapy may not be extremely effective in this unselected cohort, and not all patients with locally advanced NPC present with high-risk factors for AdjCT. Moreover, another study in Taiwan has reported that AdjCT can reduce distant failure and improve OS in patients with NPC who had persistently detectable \textit{EBV} DNA after curative RT plus induction/CCRT.\textsuperscript{[29]} In our study, AdjCT does not improve survival, which may be related to factors, such as the non-selection of N3 patients who are at high risk. Prospective clinical control studies with large sample sizes must be conducted in the future.

Patients with N3 NPC are at high risk for distant metastasis, and their 5-year survival rate is poor. The more important prognostic factors are T stage and chemotherapy. In this study, radiotherapy combined with different methods of chemotherapy has an effect on N3 NPC. Further discussion must be conducted in prospective studies.

Figure 3. DMFS between patients who received IndCT plus CCRT and CCRT alone. CCRT = concurrent chemotherapy, DMFS = distant metastasis-free survival, IndCT = induced chemotherapy.
Figure 4. Five-year OS between patients who received CCRT plus AdjCT and CCRT alone. AdjCT = adjuvant chemotherapy, CCRT = concurrent chemotherapy, OS = overall survival.

Figure 5. DFS between patients who received CCRT plus AdjCT and CCRT alone. AdjCT = adjuvant chemotherapy, CCRT = concurrent chemotherapy, DFS = disease-free survival.
Author contributions

Conceptualization: Fujun Hu.
Data curation: Jing Chen, Fujun Hu.
Formal analysis: Jing Chen.
Funding acquisition: Tongxin Liu, Quanquan Sun.
Methodology: Jing Chen, Tongxin Liu, Fujun Hu.
Resources: Jing Chen, Quanquan Sun.
Software: Jing Chen.
Supervision: Fujun Hu.
Validation: Jing Chen.
Visualization: Jing Chen.
Writing – original draft: Jing Chen, Tongxin Liu, Quanquan Sun.
Writing – review & editing: Jing Chen.

References

[1] Surveillance Epidemiology and End Results Program, 1973–2000 Division of Cancer Control and Population Sciences. 2003;NCI.
[2] Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310–7.
[3] Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002;52:1238–44.
[4] Kwon DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004;22:2643–53.
[5] Rossi A, Molinari R, Boracchi P, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988;6:1401–10.
[6] Teo PML, Kwan WH, Lee WY, et al. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996;77:2423–31.
[7] Lin J, Jan JS, Hsu CY. Outpatient weekly chemotherapy in patients with nasopharyngeal carcinoma and distant metastasis. Cancer 1998;83:635–40.
[8] Ong YK, Heng DM, Chung B, et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer 2003;39:1335–41.
[9] Toh CK, Heng D, Ong YK, et al. Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer 2005;92:1382–7.
[10] Pepin E, Katinou K, Tasiou I, et al. 3D conformal radiotherapy in primary nasopharyngeal cancer: effectiveness and prognostic factors. J BUON 2015;20:514–20.
[11] Tan T, Lim WT, Fong KW, et al. Concurrent Chemo-Radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2015;91:952–60.
[12] Zhang LN, Gao YH, Lan XW, et al. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a large scale propensity-matched study. Oral Oncol 2015;51:950–6.
[13] Guo NS, Tang IQ, Zhan GL, et al. The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. BMC Cancer 2015;16:977.
[14] Bautar B, Bourhis J, Chan AT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1733 patients. Int J Radiat Oncol Biol Phys 2006;64:47–56.
[15] Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004;22:4604–12.
[16] Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015;16:645–55.
[17] Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer 2013;119:963–70.
[18] Lee AWM, Ng WT, Chan OSH, et al. If concurrent-adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal
carcinoma, would changing the sequence to induction-concurrent achieve better outcome. J Radiat Oncol 2012;1:107–15.

[19] Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631–7.

[20] Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol 1998;16:1310–7.

[21] Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002;20:2038–44.

[22] Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536–9.

[23] Zhang L, Zhao C, Peng PJ, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005;23:8461–8.

[24] Lin JC, Jan JS, Hsu CY, et al. Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates. Br J Cancer 2003;88:187–94.

[25] Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225. J Clin Oncol 2009;27:3684–90.

[26] Lee N, Zhang Q, Pfister D, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012;13:172–80.

[27] Cho JK, Lee GJ, Yi Ki, et al. Development and external validation of nomograms predictive of response to radiation therapy and overall survival in nasopharyngeal cancer patients. Eur J Cancer 2015;51:1303–11.

[28] Chen L, Hu CS, Chen NZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicenter randomized controlled trial. Lancet Oncol 2012;13:163–71.

[29] Chih-Wen , Twu , Wen-Yi Wang , et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. IJROBP 2014;89:21–9.